|Chemical and physical data|
|Molar mass||144.33 kg/mol (peptide)|
|(what is this?)|
Amatuximab is a chimeric monoclonal antibody designed for the treatment of cancer.
Amatuximab was developed by Morphotek, Inc.
Amatuximab is also known as Anti-mesothelin monoclonal antibody MORAb-009. Amatuximab is an anti-mesothelin monoclonal antibody MORAb-009 binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing, and also called MORAb-009.
- Anti-mesothelin monoclonal antibody MORAb-009 entry in the public domain NCI Dictionary of Cancer Terms